US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

40.77

+0.96002.41%

Post-market: 40.50-0.2700-0.66%19:46 EST

Volume:229.48K

Turnover:9.32M

Market Cap:1.95B

PE:-19.19

High:41.44

Open:39.84

Low:39.84

Close:39.81

52wk High:43.29

52wk Low:6.71

Shares:47.85M

Float Shares:20.43M

Volume Ratio:0.66

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1250

EPS(LYR):1.42

ROE:-52.69%

ROA:-27.37%

PB:5.14

PE(LYR):28.69

Loading ...

Overview Company News Filings

Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Diseases

Maze Therapeutics Is Maintained at Buy by BTIG

Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Disease Therapies

Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares

Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale

Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares

Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares

Wedbush Raises Price Target on Maze Therapeutics to $43 From $36, Keeps Outperform Rating

MT Newswires Live

Maze Therapeutics to Present at J.P. Morgan Healthcare Conference

Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares

Maze Therapeutics Inc : Leerink Partners Raises Target Price to $50 From $34

THOMSON REUTERS

Maze Therapeutics Initiated at Overweight by Wells Fargo

Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target

MT Newswires Live

Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics

Raymond James Initiates Maze Therapeutics at Strong Buy With $48 Price Target

MT Newswires Live

Maze Therapeutics initiated with a Strong Buy at Raymond James

Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances

Maze Therapeutics Is Maintained at Outperform by Wedbush

Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":40.77,"timestamp":1768597200000,"preClose":39.81,"halted":0,"volume":229475,"hourTrading":{"tag":"盘后","latestPrice":40.5,"preClose":40.77,"latestTime":"19:46 EST","volume":2553,"amount":104091.62,"timestamp":1768610779701,"change":-0.27,"changeRate":-0.006623,"amplitude":0},"delay":0,"changeRate":0.024114544084400925,"floatShares":20434300,"shares":47850886,"eps":-2.125,"marketStatus":"Market Closed","change":0.96,"latestTime":"01-16 16:00:00 EST","open":39.84,"high":41.44,"low":39.835,"amount":9318361.0854,"amplitude":0.040317,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":39.81,"postHourTrading":{"tag":"盘后","latestPrice":40.5,"preClose":40.77,"latestTime":"19:46 EST","volume":2553,"amount":104091.62,"timestamp":1768610779701,"change":-0.27,"changeRate":-0.006623,"amplitude":0},"volumeRatio":0.6619150763430846,"impliedVol":0.4814,"impliedVolPercentile":0.2118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":20434300,"roa":"-27.37%","roe":"-52.69%","lyrEps":1.421062,"volumeRatio":0.6619150763430846,"shares":47850886,"dividePrice":0,"high":41.44,"amplitude":0.040317,"preClose":39.81,"low":39.835,"week52Low":6.71,"pbRate":"5.14","week52High":43.29,"institutionHeld":0,"latestPrice":40.77,"eps":-2.125,"divideRate":0,"volume":229475,"delay":0,"ttmEps":-2.125,"open":39.84,"prevYearClose":41.43,"prevWeekClose":40.32,"prevMonthClose":41.43,"prevQuarterClose":41.43,"fiveDayClose":40.32,"twentyDayClose":38.4,"sixtyDayClose":29.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77},{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1764910800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-01-16","current":-19.185882,"percent":0.082645,"low":-16.252058,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"high":14.99285,"avg":0.485453,"sd":10.843117,"marketCap":1915635065},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065}],"updateTime":1768765609864},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604915809","title":"Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2604915809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604915809?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:58","pubTimestamp":1768589914,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead program, MZE829, a dual-mechanism APOL1 inhibitor developed as an oral therapy for APOL1-mediated kidney disease , a condition that disproportionately affects people of African ancestry. MZE829 has advanced to a Phase 2 clinical trial, with topline proof-of-concept data expected by the end of the first quarter of 2026. The Phase 1 data demonstrated a favorable safety profile, dose-proportional pharmacokinetics, and minimal drug-drug interaction risk, supporting the selection of a 250 mg once-daily dose for Phase 2. Additional pipeline programs include MZE782 for phenylketonuria , which is Phase 2 ready with trial initiation planned for mid-2026, and a chronic kidney disease program set to begin Phase 2 in the second half of 2026. The company reports an expected cash runway into 2028. You can access the full presentation through th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL8jhJGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2604918276","title":"Maze Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604918276","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604918276?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:35","pubTimestamp":1768584900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 12:35 ET (17:35 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2603924544","title":"Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603924544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603924544?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:07","pubTimestamp":1768234077,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has provided an update on its pipeline focused on kidney and metabolic diseases. The company highlighted progress with its lead program, MZE829, a dual-mechanism APOL1 inhibitor in development for APOL1-mediated kidney disease , which disproportionately affects individuals of African ancestry. MZE829 is currently enrolling in a Phase 2 study, with topline proof-of-concept data expected by the end of Q1 2026. The candidate has demonstrated a favorable safety profile and predictable pharmacokinetics in Phase 1 studies, supporting the selection of a 250 mg once-daily dose for further evaluation. Additional programs in the pipeline include MZE782 for phenylketonuria , with plans to initiate Phase 2 trials by mid-2026, and a chronic kidney disease program expected to enter Phase 2 in the second half of 2026. Maze Therapeutics reports a cash runway extending into 2028 based on its current business plan. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6YYDpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2602010503","title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602010503","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602010503?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:52","pubTimestamp":1767995523,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9FT0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2602348531","title":"Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348531","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348531?lang=en_us&edition=fundamental","pubTime":"2026-01-09 10:03","pubTimestamp":1767924208,"startTime":"0","endTime":"0","summary":"New insider activity at Maze Therapeutics, Inc. ( ($MAZE) ) has taken place on January 8, 2026. Director Catherine Sohn has offloaded 29,413 shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/maze-therapeutics-director-makes-major-insider-move-with-high-value-stock-sale-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/maze-therapeutics-director-makes-major-insider-move-with-high-value-stock-sale-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2602138023","title":"Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602138023","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602138023?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:31","pubTimestamp":1767907884,"startTime":"0","endTime":"0","summary":"Catherine A. Sohn, Director at Maze Therapeutics Inc., has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4n8TtX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2601684311","title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601684311","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601684311?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:32","pubTimestamp":1767735155,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & CMO of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLmKTY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2601892896","title":"Wedbush Raises Price Target on Maze Therapeutics to $43 From $36, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892896","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892896?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:26","pubTimestamp":1767702413,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $47.89, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2601885705","title":"Maze Therapeutics to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885705","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885705?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614415,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company focused on precision medicines for kidney and metabolic diseases, will participate in the 44th Annual J.P. Morgan Healthcare Conference. Jason Coloma, Ph.D., chief executive officer, is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. PT. A live webcast of the presentation will be available on the Maze Therapeutics website and archived for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL3xJ0hy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","BK4007","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","SG9999014005.SGD","MAZE"],"gpt_icon":0},{"id":"2600701572","title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701572","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701572?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:24","pubTimestamp":1767216296,"startTime":"0","endTime":"0","summary":"Atul Dandekar, Chief Strategy and Business Officer  of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL16Wz74:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2592908597","title":"Maze Therapeutics Inc : Leerink Partners Raises Target Price to $50 From $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908597?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:54","pubTimestamp":1766058871,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2588873168","title":"Maze Therapeutics Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2588873168","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588873168?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:49","pubTimestamp":1764856140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 08:49 ET (13:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2588382881","title":"Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588382881?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:22","pubTimestamp":1764850969,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Coverage on Maze Therapeutics With Overweight Rating, $55 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2588026773","title":"Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588026773","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588026773?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:29","pubTimestamp":1764790140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 14:29 ET (19:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2583685349","title":"Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685349","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685349?lang=en_us&edition=fundamental","pubTime":"2025-11-15 01:31","pubTimestamp":1763141476,"startTime":"0","endTime":"0","summary":"RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) has shared an update. Relief Therapeutics Holding SA announced that its shareholders have approved a busi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relief-therapeutics-to-merge-with-neurox-forming-mindmaze-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relief-therapeutics-to-merge-with-neurox-forming-mindmaze-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2583849509","title":"Raymond James Initiates Maze Therapeutics at Strong Buy With $48 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2583849509","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583849509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:13","pubTimestamp":1763126033,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has an average rating of buy and mean price target of $40.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","MAZE"],"gpt_icon":0},{"id":"2583351239","title":"Maze Therapeutics initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351239?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:11","pubTimestamp":1763068264,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target Maze’s lead wholly-owned assets – MZE829...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","LU1363072403.SGD","LU2265009873.SGD","IE00B64PRP62.GBP","BK4127","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","LU0971096721.USD","BK4007","RJF","LU1804176565.USD","BK4588"],"gpt_icon":0},{"id":"2581880691","title":"Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581880691?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:56","pubTimestamp":1762534561,"startTime":"0","endTime":"0","summary":"In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $50.00. An...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-maze-therapeutics-pipeline-buy-rating-reinforced-by-mze829-and-mze782-advances-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-maze-therapeutics-pipeline-buy-rating-reinforced-by-mze829-and-mze782-advances-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2581788466","title":"Maze Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2581788466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581788466?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:16","pubTimestamp":1762528560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 10:16 ET (15:16 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2581046509","title":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046509","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046509?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:02","pubTimestamp":1762466550,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706288/maze-therapeutics-q3-eps-0-66-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maze Therapeutics Q3 EPS $(0.66) Beats $(0.71) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":74,"code":"91000000","status":"200"}]}}